DNAJA2

Across TCGA pan-cancer cohorts, DNAJA2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DNAJA2 data layer compared with 14 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher DNAJA2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated DNAJA2 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, LUAD, and UCEC are the cancer types where DNAJA2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.472	0.300	.007	20	view →
LUAD	DFS	Tertile	All	0.458	0.830	.006	12	view →
UCEC	OS	Tertile	All	0.819	0.977	.016	6	view →
LSCC	OS	Tertile	All	0.821	0.916	.047	1	view →
CCRCC	DFS	Median	All	0.583	0.853	.024	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DNAJA2–PDAC (DFS)

Open the PDAC breakdown →